Market Cap 858.75M
Revenue (ttm) 23.68M
Net Income (ttm) -318.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,346.11%
Debt to Equity Ratio 1.60
Volume 1,733,000
Avg Vol 1,922,282
Day's Range N/A - N/A
Shares Out 86.05M
Stochastic %K 42%
Beta 0.74
Analysts Strong Sell
Price Target $32.33

Company Profile

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 419 1400
Website: syndax.com
Address:
730 Third Avenue, 9th Floor, New York, United States
CH_Expat
CH_Expat Aug. 4 at 1:50 PM
$SNDX $TGTX after 20% earnings miss selloff still trades at 3x peak sales while we trade at cash plus 2025 revenue.
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Aug. 3 at 6:12 PM
Even a casual review of stock price graphs of commercial-stage oncology focused bios tells you last week was tough on this peer group that historically outperforms non-oncology (as multiples of projected revenues). This coming week is, arguably, the most exciting of the quarter when a majority of bios with FDA approved therapies report on their launches. This is why it is puzzling most oncology shares did so poorly as there appears no really bad news. In fact it appears $INCY did well. $DAWN hit $7.37 then fell down at a 45 degree angle before recovering Friday The attached table lists the 8/1/25 closing share prices and change in share price from the previous week's closing high for all 27 commercial-stage oncology focused bios with market caps north of $150MM (excl. RIGL). Half were off by more than 10% & 2/3 were off by more than 7%. $URGN what can you say :) This is not investment advice but we still like $SNDX as we believe INCY will acquire them by year end. $DCTH
2 · Reply
Tomasini
Tomasini Aug. 2 at 2:06 PM
$SNDX price to sales of 8.5 is about inline. EPS willbe negative again around -$1.00 or so. I doubt we see much gain Monday night, esp. with heavy shorting
0 · Reply
rabbitsoup
rabbitsoup Aug. 2 at 1:59 AM
$SNDX Mon. afternoon will surely be interesting. There is a huge, short position at these levels. They are either correct and expect to find massive liquidity to cover at lower levels or hopefully they've overplayed their hand and are going to feel the pain shorts deserve for betting against life-saving drugs. Your guess as good as mine...
0 · Reply
CrispDry
CrispDry Aug. 1 at 11:44 PM
$SNDX gonna be a stellar week next week $TARS
0 · Reply
Magnificient
Magnificient Aug. 1 at 9:53 PM
$IOVA Good night from Istanbul $AUPH $SNDX
4 · Reply
Samalex
Samalex Aug. 1 at 8:30 PM
$ARDX and $SNDX are scheduled to release their earning reports during the after hours on Monday, August 4th. Looking forward to hearing sales numbers of their respective FDA approved drugs.
0 · Reply
keypatience
keypatience Aug. 1 at 6:05 PM
$SNDX PDUFA date: October 25, 2025
0 · Reply
sck2
sck2 Aug. 1 at 3:30 PM
$SNDX what do you expect earnings will be? tia
0 · Reply
CH_Expat
CH_Expat Jul. 31 at 4:26 PM
$SNDX Put a buy order of 1000 for 9.99 for the fun of it. Bid jumps to 10.10 within one minute. Nothing to see here.
2 · Reply
Latest News on SNDX
Syndax Announces Participation in June Investor Conferences

May 29, 2025, 7:00 AM EDT - 2 months ago

Syndax Announces Participation in June Investor Conferences


Syndax Announces Participation in May Investor Conferences

May 8, 2025, 7:00 AM EDT - 3 months ago

Syndax Announces Participation in May Investor Conferences


Syndax Announces Participation in March Investor Conferences

Feb 25, 2025, 7:00 AM EST - 5 months ago

Syndax Announces Participation in March Investor Conferences


Syndax Announces Participation in February Investor Conferences

Jan 30, 2025, 7:00 AM EST - 6 months ago

Syndax Announces Participation in February Investor Conferences


US FDA approves Syndax's blood cancer drug

Nov 15, 2024, 6:26 PM EST - 9 months ago

US FDA approves Syndax's blood cancer drug


Syndax Announces Participation in November Investor Conferences

Nov 1, 2024, 7:00 AM EDT - 9 months ago

Syndax Announces Participation in November Investor Conferences


FDA Delays Decision on Syndax Leukemia Drug; Stock Sinks

Jul 29, 2024, 2:51 PM EDT - 1 year ago

FDA Delays Decision on Syndax Leukemia Drug; Stock Sinks


CH_Expat
CH_Expat Aug. 4 at 1:50 PM
$SNDX $TGTX after 20% earnings miss selloff still trades at 3x peak sales while we trade at cash plus 2025 revenue.
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Aug. 3 at 6:12 PM
Even a casual review of stock price graphs of commercial-stage oncology focused bios tells you last week was tough on this peer group that historically outperforms non-oncology (as multiples of projected revenues). This coming week is, arguably, the most exciting of the quarter when a majority of bios with FDA approved therapies report on their launches. This is why it is puzzling most oncology shares did so poorly as there appears no really bad news. In fact it appears $INCY did well. $DAWN hit $7.37 then fell down at a 45 degree angle before recovering Friday The attached table lists the 8/1/25 closing share prices and change in share price from the previous week's closing high for all 27 commercial-stage oncology focused bios with market caps north of $150MM (excl. RIGL). Half were off by more than 10% & 2/3 were off by more than 7%. $URGN what can you say :) This is not investment advice but we still like $SNDX as we believe INCY will acquire them by year end. $DCTH
2 · Reply
Tomasini
Tomasini Aug. 2 at 2:06 PM
$SNDX price to sales of 8.5 is about inline. EPS willbe negative again around -$1.00 or so. I doubt we see much gain Monday night, esp. with heavy shorting
0 · Reply
rabbitsoup
rabbitsoup Aug. 2 at 1:59 AM
$SNDX Mon. afternoon will surely be interesting. There is a huge, short position at these levels. They are either correct and expect to find massive liquidity to cover at lower levels or hopefully they've overplayed their hand and are going to feel the pain shorts deserve for betting against life-saving drugs. Your guess as good as mine...
0 · Reply
CrispDry
CrispDry Aug. 1 at 11:44 PM
$SNDX gonna be a stellar week next week $TARS
0 · Reply
Magnificient
Magnificient Aug. 1 at 9:53 PM
$IOVA Good night from Istanbul $AUPH $SNDX
4 · Reply
Samalex
Samalex Aug. 1 at 8:30 PM
$ARDX and $SNDX are scheduled to release their earning reports during the after hours on Monday, August 4th. Looking forward to hearing sales numbers of their respective FDA approved drugs.
0 · Reply
keypatience
keypatience Aug. 1 at 6:05 PM
$SNDX PDUFA date: October 25, 2025
0 · Reply
sck2
sck2 Aug. 1 at 3:30 PM
$SNDX what do you expect earnings will be? tia
0 · Reply
CH_Expat
CH_Expat Jul. 31 at 4:26 PM
$SNDX Put a buy order of 1000 for 9.99 for the fun of it. Bid jumps to 10.10 within one minute. Nothing to see here.
2 · Reply
dcrown
dcrown Jul. 31 at 4:19 PM
$SNDX “confidence in Niktimvo's potential, noting its current market penetration of approximately 10% in the third-line plus chronic GVHD market. They believe that future potential will be enhanced by exploring combinations with Jakafi and steroids, and developing a subcutaneous formulation. The current launch trajectory suggests Niktimvo could perform similarly to or better than other approved treatments in the chronic GVHD space, especially if it secures additional indications. indicates Niktimvo's role in driving robust revenue growth for Incyte. The company also raised its full-year 2025 guidance for Other Oncology products, which includes Niktimvo, to a new range of $500 - $520 million, signaling their optimism about the product's future performance
0 · Reply
justiceforb_85
justiceforb_85 Jul. 31 at 3:53 PM
$SNDX adding. They have two FDA approved medicines. Market cap way too low.
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Jul. 31 at 3:20 PM
$SNDX Looks bullish. Anyone with a bear case here? Patents expiry/market penetration/competition
1 · Reply
kriscory69
kriscory69 Jul. 30 at 7:19 PM
$SNDX started a position here
0 · Reply
CH_Expat
CH_Expat Jul. 30 at 5:54 PM
$SNDX Stock price movement is a joke, completely manipulated by algos and shorts. One day it will climb 50% within two weeks.
2 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jul. 30 at 1:56 PM
While $SNDX partner $INCY reported compelling Niktimvo Q225 sales yesterday morning, SNDX reports Q225 Revuforj sales next week. Because INCY reports Niktimvo sales, SNDX analyst revenue estimates reflect Revuforj only (outside some ex-US Niktimvo royalties). Rezurock non-US sales were not 5% of the US in its 1st 3 years. In Q125, Rezurock ex-US sales were ~16% of US Of the 11 analysts that cover SNDX, 3 provide consistent longer-term peak sales ests north of $1B/year. Attached is a comparison of SNDX 10-year analyst revenue estimates compared to like estimates from 6 SNDX peers whose mgmt (not analysts) projected roughly the same $750 - $1B peak sales profile. All were acquired for $1.7 to $2.2B. If SNDX analyst estimates are credible & if Revuforj is worth a M&A revenue multiple consistent with these 6 peers (2 HUGE IFs) then is it possible Revuforj is worth a like valuation should SNDX exit via M&A? What about Niktimvo ($RPRX)? We'd genuinely appreciate perspectives. $XBI
1 · Reply
heweg11
heweg11 Jul. 30 at 1:39 PM
$SNDX Potential buyout target for $ABBV? Two first-in-class drugs (Revumenib + Niktimvo), early commercial traction, and fits AbbVie’s oncology + fibrosis strategy. Looks very bullish.
1 · Reply
heweg11
heweg11 Jul. 30 at 12:54 PM
0 · Reply
Magnificient
Magnificient Jul. 30 at 5:08 AM
$SNDX pre PDUFA run if ER is clear. And it will be. Buy know what is $11 ?
0 · Reply
JcoalX
JcoalX Jul. 30 at 1:04 AM
0 · Reply
Samalex
Samalex Jul. 29 at 9:43 PM
Looking forward to hearing: $SNDX earnings 8/4 $ARDX earnings 8/4 $NUVB earnings 8/7
0 · Reply
Jarvis7424
Jarvis7424 Jul. 29 at 6:52 PM
$SNDX if we can break $11.2 by Friday that would be huge
1 · Reply